Chengying Xie

YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor‐2 tyrosine kinase with potent activity <i>in vitro</i> and <i>in vivo</i>

Shu Tian, Haitian Quan, Chengying Xie et al. · Cancer Science · 2011 · 521 citations · Full text

Medicine, Oncology, Pharmacology +17

Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor

Chengying Xie, Xiaozhe Wan, Haitian Quan et al. · Cancer Science · 2018 · 371 citations · Full text

Medicine, Oncology, Pharmacology +17

Novel potato C2H2-type zinc finger protein gene, StZFP1, which responds to biotic and abiotic stress, plays a role in salt tolerance

Zhendong Tian, Y. Zhang, J. Liu et al. · Plant Biology · 2009 · 108 citations

Life Sciences, Plant Biology, Plant Sciences +15

Pharmacologic characterization of fluzoparib, a novel poly(<scp>ADP</scp>‐ribose) polymerase inhibitor undergoing clinical trials

Lei Wang, Changyong Yang, Chengying Xie et al. · Cancer Science · 2019 · 93 citations · Full text

Medicine, Oncology, Pharmacology +16

Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models

Fei Long, Ye He, Haoyu Fu et al. · Cancer Science · 2019 · 83 citations · Full text

Medicine, Oncology, Pharmacology +15